ストックスクリーナーアプリを入手
1.45
2.03%
-0.03
プレマーケット:
1.44
-0.01
-0.69%
前日終値:
$1.48
開ける：
$1.46
24時間の取引高:
26,932
Relative Volume:
0.02
時価総額：
$9.85M
収益：
-
当期純損益:
$-11.46M
株価収益率:
-0.1036
EPS:
-14
ネットキャッシュフロー:
$-24.56M
1週間 パフォーマンス:
-7.05%
1か月 パフォーマンス:
+5.07%
6か月 パフォーマンス:
-88.40%
1年 パフォーマンス:
-92.51%
1日の値動き範囲:
$1.43
$1.50
1週間の範囲:
$1.42
$1.62
52週間の値動き範囲:
$1.20
$20.81
Evaxion Biotech A S Adr Stock (EVAX) Company Profile
EVAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EVAX
Evaxion Biotech A S Adr
|
1.45 | 9.85M | 0 | -11.46M | -24.56M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.60 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.67 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
569.12 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.35 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
235.94 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Evaxion Biotech A S Adr Stock (EVAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-02 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2024-02-12 | 開始されました | H.C. Wainwright | Buy |
Evaxion Biotech A S Adr (EVAX) 最新ニュース
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - GlobeNewswire Inc.
EVAX: Cancer Vaccine Shows Great Results - Research Tree
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
European Stocks Slip In US Trading With Mixed Performances - Finimize
Evaxion Biotech’s Optimistic Earnings Call Highlights - TipRanks
Evaxion Biotech Reports 2024 Financial Results and Strategic Progress - TipRanks
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
Evaxion Biotech stock plunges to 52-week low of $1.66 - Investing.com
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
Evaxion Biotech stock plunges to 52-week low of $1.7 amid steep annual decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - TradingView
European Equities Traded in the US as ADRs Fall in Tuesday Trading - TradingView
Evaxion Biotech stock hits 52-week low at $1.79 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
EVAX: Extended Trial is Excellent News - Research Tree
Evaxion Biotech A/SADR to Host Earnings Call - ACCESS Newswire
Evaxion Biotech stock hits 52-week low at $2.22 amid sharp decline - Investing.com
Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading - TradingView
Evaxion Biotech A/S ADR (EVAX) Receives Upgrades Amid Sharp Decline – Is It Time for Investors to Reevaluate? - HPBL
Evaxion Biotech (EVAX) Stock Analysis: Price Decline, Analyst Ratings and Financial Ratios – market - HPBL
Evaxion secures Nasdaq listing with equity boost - Investing.com
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
After A Decline Of -818.6% From The High, Can Evaxion Biotech A/S ADR (NASDAQ: EVAX) Recover Quickly? - Marketing Sentinel
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, End Week Up 3.2% - TradingView
Top investors say Evaxion Biotech A/S ADR (EVAX) ticks everything they need - SETE News
Evaxion Biotech A/S ADR [EVAX] Investment Guide: What You Need to Know - Knox Daily
Now Is The Time To Build A Position In Evaxion Biotech A/S ADR (NASDAQ:EVAX) - Marketing Sentinel
Evaxion Biotech A/S ADR (EVAX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Palantir Technologies Surges 16.5% in Pre-Market Trading After Strong Q4 Earnings Report - HPBL
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
Spyre Therapeutics Inc (SYRE) stock analysis: A comprehensive overview - US Post News
Argo Blockchain Plc ADR (ARBK)’s stock price in review: A technical analysis - US Post News
Evaxion Biotech A/S ADR (EVAX)’s stock decline to 2.40 per share - US Post News
Daily Market Movement: Onconetix Inc (ONCO) Sees a 11.91 Increase, Closing at 0.61 - The Dwinnex
In the Green: Evaxion Biotech A/S ADR (EVAX) Closes at 2.40, Up/Down -2.24 from Previous Day - The Dwinnex
Market Insights: Kairos Pharma Ltd (KAPA)’s Notable Gain of 6.29, Closing at 1.52 - The Dwinnex
Palantir Technologies at a Crossroads: Sky-High Valuation or Looming Market Correction? - HPBL
Hodges Capital Management Takes $16.5 Million Stake in Palantir Technologies (PLTR) – market - HPBL
H.C. Wainwright maintains Evaxion stock Buy rating, $14 target - Investing.com
Major Pharma Giant's VC Fund Doubles Down on Evaxion Biotech in $10.8M Strategic Round - StockTitan
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - TradingView
Evaxion Biotech stock hits 52-week low at $2.38 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Tread Water in Monday Trading - MSN
When Will Evaxion Biotech A/S ADR. (EVAX) Be Worth Investing In? - Marketing Sentinel
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gains 2% for Week - MSN
Investing Now Could Prove Beneficial For Evaxion Biotech A/S ADR (NASDAQ: EVAX) - Marketing Sentinel
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading - MSN
Evaxion Biotech A S Adr (EVAX) 財務データ
収益
当期純利益
現金流量
EPS
5.73%
1.07%
大文字化:
|
ボリューム (24 時間):